Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 208

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 208
---
             |     | (35,040 | ) |
| Balance - September 30, 2024 |     | 348,971 |   |
| Current                      |     | 112,387 |   |
| Non-current                  |     | 236,584 |   |

<div align='center'>F-11</div>

The following table sets out a maturity analysis of the lease payments payable, showing the undiscounted lease payments to be paid on an annual basis, reconciled to the lease obligation as follows:

|                                           |     |       $ |   |
| Less than one year                        |     | 141,211 |   |
| One to two years                          |     | 145,448 |   |
| Thereafter                                |     | 111,522 |   |
| Total undiscounted lease payments payable |     | 398,181 |   |
| Less: impact of present value             |     | (49,210 | ) |
| Balance - September 30, 2024              |     | 348,971 |   |

Expenses for the three and nine months ended September 30, 2024, relating to leases of short-term and low-value leases, were $1,508 and $4,524 (2023 - $nil and $nil).

4. Convertible notes

On May 3, 2024, the Company issued convertible notes in the principal amount of $5,172,500. The convertible notes accrued interest at the rate of 10% per annum, payable in-kind semi-annually in arrears in the form of either cash or common shares of the Company, at the election of the holder, and had a maturity date of December 31, 2025.

Prior to January 1, 2025, the convertible notes would automatically convert to common shares in the event that the Company completed an initial public offering in the United States, at a conversion price equal to the greater of (i) a 20% discount to the initial public offering price and (ii) US$4.00; or if there had been a change of control, at a conversion price of $4.00 per common share. On or after January 1, 2025, conversion would be at the option of the holder at a conversion price of $4.00 per common share. The Company had the option to redeem all or any portion of the convertible notes at a price equal to 100% of the outstanding principal plus